For example, the upregulation of Proline-, glutamic acid-and leucine-rich protein1 (PELP1), an oestrogen receptor coactivator and proto-oncogene, has been reported to be associated with poor prognosis in breast cancer patients (Habashy et al., 2010), and with resistance to endocrine therapy in vitro (Flågeng et al., 2015). Here, PELP1 is linked to breast cancer.